Budesonide (inhaled)

Budesonide is a potent inhaled corticosteroid widely used in equine medicine for the management of respiratory conditions characterized by airway inflammation. This synthetic glucocorticoid belongs to the same class as other inhaled steroids but possesses unique pharmacokinetic properties that make it particularly suitable for respiratory therapy. Budesonide has become one of the most commonly prescribed inhaled corticosteroids for horses with equine asthma syndrome, encompassing conditions such as recurrent airway obstruction (RAO), heaves, and inflammatory airway disease (IAD). By delivering anti-inflammatory medication directly to the respiratory tract via inhalation, budesonide provides targeted treatment while minimizing systemic corticosteroid exposure.

The mechanism of action of budesonide involves multiple anti-inflammatory pathways that work together to reduce airway inflammation and improve respiratory function. Upon reaching the bronchial epithelium and underlying tissues, budesonide binds to glucocorticoid receptors within cells, triggering a cascade of anti-inflammatory effects. These include decreased production of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes, as well as reduced recruitment of inflammatory cells to the airways. Budesonide also decreases airway mucus production and reduces swelling of the bronchial walls, resulting in improved airway patency. One notable characteristic of budesonide is its high first-pass hepatic metabolism when absorbed systemically, which means that any drug reaching the systemic circulation is rapidly inactivated by the liver, reducing the risk of systemic side effects compared to some other corticosteroids.

Budesonide for equine use is available in several formulations, including nebulizer suspensions and metered-dose inhalers. Nebulization involves converting the liquid medication into a fine mist that can be inhaled through a specialized equine mask over a treatment period of 10 to 20 minutes. This delivery method is effective for reaching the lower airways and is particularly useful for horses with severe disease or those who do not tolerate metered-dose inhaler administration. Metered-dose inhaler delivery uses an equine-specific spacer device that holds the aerosolized medication while the horse breathes, allowing drug particles to be carried into the lungs. Both delivery methods have proven effective, and the choice often depends on equipment availability, horse cooperation, and owner preference.

While inhaled budesonide offers significant advantages over systemic corticosteroid therapy in terms of reduced side effects, proper veterinary diagnosis and supervision are essential for optimal outcomes. Equine asthma should be confirmed through appropriate diagnostic evaluation before initiating treatment, as other respiratory conditions may require different therapeutic approaches. The veterinarian will establish the appropriate dosing regimen based on disease severity, select the optimal delivery method, and monitor treatment response through follow-up examinations. Horse owners must be trained in proper administration technique to ensure effective drug delivery to the lungs. Consistent treatment adherence and concurrent environmental management are critical components of successful therapy.

The primary indication for inhaled budesonide in horses is the management of equine asthma syndrome, a spectrum of inflammatory respiratory conditions affecting horses of all ages and disciplines. Equine asthma ranges from mild inflammatory airway disease (IAD) commonly seen in young performance horses to severe recurrent airway obstruction (RAO or heaves) causing significant respiratory distress. These conditions share underlying airway inflammation, bronchospasm, and excessive mucus production as common features. Inhaled corticosteroids like budesonide address the inflammatory component, providing long-term disease control when used consistently alongside appropriate environmental management.

Horses with severe equine asthma, historically termed heaves or recurrent airway obstruction, represent a population that frequently benefits from inhaled budesonide therapy. These horses exhibit pronounced respiratory signs including increased respiratory rate and effort, nostril flaring, and the characteristic abdominal component to breathing that results from chronic use of accessory muscles. A visible heave line may develop along the horse's flank from chronic respiratory effort. Severe disease often develops in response to inhaled allergens including hay dust, mold spores, and barn environmental particles. While environmental modification remains essential, inhaled budesonide helps control the underlying inflammation and improves quality of life. Many severe cases require initial stabilization with systemic corticosteroids before transitioning to inhaled maintenance therapy.

Inflammatory airway disease (IAD) represents the milder end of the equine asthma spectrum and is particularly common in young performance horses, with some studies suggesting prevalence rates exceeding 50% in certain populations. IAD manifests as poor performance, intermittent coughing, exercise intolerance, and increased tracheal mucus without the severe respiratory distress characteristic of RAO. This condition can significantly impact athletic performance and racing or competition success. Inhaled budesonide provides effective treatment for IAD while minimizing systemic corticosteroid exposure that could affect metabolism, immune function, or competition eligibility. Early treatment of IAD may help prevent progression to more severe disease.

Beyond equine asthma syndrome, inhaled budesonide may be incorporated into treatment protocols for other conditions involving lower airway inflammation. Some veterinarians include inhaled corticosteroids in the management of chronic bronchitis or post-infectious airway inflammation after resolution of the primary infection. The medication may also be useful in managing airways reactivity that persists following acute respiratory illness. In some cases, inhaled budesonide serves as a transition medication when weaning horses from systemic corticosteroid therapy, allowing gradual reduction of systemic treatment while maintaining airway inflammation control.

Selection of budesonide over other treatment options depends on multiple factors including disease severity, owner capability for medication administration, equipment availability, and competition considerations. For mild to moderate equine asthma, inhaled therapy combined with environmental management may suffice as primary treatment. For severe disease, inhaled corticosteroids typically serve as maintenance therapy following initial systemic treatment. Budesonide's high first-pass hepatic metabolism provides potential advantages in terms of reduced systemic absorption compared to some other inhaled corticosteroids, which may be particularly relevant for performance horses or those at risk for corticosteroid-related complications.

Dosing protocols for inhaled budesonide in horses must be determined by a veterinarian based on the diagnosis, disease severity, chosen delivery method, and individual patient response. Unlike oral medications where dosing is calculated based on body weight, inhaled budesonide dosing involves specifying the concentration of the medication, the amount or number of actuations delivered, and the treatment frequency. The goal is to deliver sufficient medication to the airways to control inflammation while minimizing both local and systemic exposure. Because budesonide formulations designed for human use are used off-label in horses, veterinary expertise is essential for appropriate dosing.

For nebulizer administration, budesonide is typically provided as a nebulizer suspension that is placed in the nebulizer cup and converted to an inhalable mist. Common protocols involve nebulizing budesonide suspension once or twice daily, with the total daily dose ranging from approximately 1000 to 3000 micrograms depending on disease severity and veterinary recommendations. Nebulization treatments typically require 10 to 20 minutes for complete delivery, during which time the horse wears an equine nebulizer mask that covers the nostrils. The specific concentration of budesonide suspension and the volume nebulized determine the total dose delivered. Higher doses may be used initially to achieve disease control, with subsequent reduction to the lowest effective maintenance dose.

Metered-dose inhaler (MDI) administration involves using an equine spacer device attached to a budesonide MDI. The number of actuations required depends on the concentration of the specific inhaler being used. Treatment is typically administered twice daily, with the total daily dose similar to that achieved through nebulization. The spacer device is held over one nostril while the other is occluded, the inhaler is actuated to release medication into the chamber, and the horse is allowed to breathe through the device for several breaths. This process is repeated for the prescribed number of actuations and then repeated on the other nostril. Proper technique is essential for effective drug delivery.

Treatment duration varies based on clinical circumstances and treatment goals. Acute exacerbations may be managed with short-term intensive therapy lasting days to weeks, while chronic equine asthma typically requires long-term or indefinite maintenance treatment. Many horses need daily inhaled corticosteroid therapy to maintain disease control. The veterinarian will establish follow-up schedules to evaluate treatment response through clinical examination, endoscopy, bronchoalveolar lavage analysis, or lung function testing. Based on these assessments, therapy may be adjusted by increasing or decreasing the dose or treatment frequency. Attempting to discontinue inhaled therapy prematurely often results in return of respiratory symptoms.

If a scheduled dose is missed, administer the treatment as soon as remembered unless the next dose is imminent. Do not double doses to compensate for missed treatments. Consistent administration is important because inhaled corticosteroids work through gradual control of underlying inflammation rather than immediate symptom relief. Sporadic use results in suboptimal disease control. Horse owners should establish a routine treatment schedule and use reminders if needed to maintain consistency.

Completing the prescribed treatment regimen and avoiding premature discontinuation are important for optimal outcomes. Even when respiratory symptoms appear resolved, underlying airway inflammation may persist and can quickly return if treatment stops. The veterinarian will provide guidance on appropriate tapering strategies if discontinuation is considered. Environmental management measures must be maintained throughout treatment, as inhaled medication cannot overcome ongoing allergen exposure. Regular follow-up allows assessment of disease control, monitoring for side effects, and optimization of the treatment plan.

Inhaled budesonide is generally well-tolerated in horses when used at appropriate doses under veterinary supervision. The inhaled route of administration provides localized drug delivery to the respiratory tract, resulting in a more favorable side effect profile compared to systemic corticosteroids. However, horse owners should be aware of potential adverse effects to monitor for during treatment. Most side effects associated with inhaled budesonide are local effects in the respiratory tract, though systemic effects can occur particularly with higher doses or prolonged therapy.

Local effects in the upper airway and oral cavity represent the most commonly observed side effects of inhaled budesonide therapy. Some horses may cough or show signs of pharyngeal irritation during or immediately after medication administration. A portion of inhaled medication is deposited in the mouth, throat, and upper airways rather than reaching the lungs. This upper airway deposition can occasionally lead to fungal overgrowth (candidiasis or thrush) in the oral cavity, though this appears less common in horses than in humans. Signs of oral fungal infection may include white patches in the mouth or altered eating behavior. Offering water or allowing the horse to eat hay after treatment may help reduce residual drug in the oral cavity.

The immunosuppressive effects of corticosteroids in the respiratory tract, while therapeutically beneficial for controlling inflammation, may theoretically increase susceptibility to respiratory infections. Horses receiving long-term inhaled budesonide should be monitored for signs of respiratory infection such as fever, nasal discharge, productive cough, or changes in breathing pattern. If infection is suspected during treatment, veterinary evaluation is needed to determine appropriate management, which may include temporary discontinuation of inhaled therapy, antimicrobial treatment, or both. The clinical decision balances the risk of infection against the benefits of continued inflammation control.

Systemic side effects are generally less common and less severe with inhaled budesonide compared to systemic corticosteroid administration due to the lower total body exposure and budesonide's high first-pass hepatic metabolism. However, some systemic absorption occurs from the respiratory tract, and horses receiving high doses or long-term treatment may experience effects similar to those seen with systemic corticosteroids. These can include increased susceptibility to infections, effects on wound healing, and rarely, alterations in glucose metabolism or adrenal function. Horses with metabolic conditions such as equine metabolic syndrome or pituitary pars intermedia dysfunction warrant careful monitoring, as any corticosteroid exposure may potentially affect disease control.

Serious adverse reactions requiring immediate veterinary attention are uncommon with inhaled budesonide but should be recognized. Severe allergic reactions to the medication or delivery system components, acute respiratory distress, or marked behavioral changes warrant prompt evaluation. While laminitis risk is lower with inhaled therapy than systemic corticosteroid administration, this remains a concern particularly in predisposed horses. Any signs of foot pain, reluctance to move, increased digital pulses, or heat in the feet should be reported immediately to the veterinarian. Contact the veterinarian also if expected improvement does not occur, if symptoms worsen, or if new concerns develop during treatment.

Inhaled budesonide is contraindicated in horses with known hypersensitivity to budesonide, other corticosteroids, or any components of the formulation being used. Horses that have experienced allergic reactions to inhaled medications, including other inhaled corticosteroids, should be identified and alternative treatment approaches considered. Signs of hypersensitivity may include acute worsening of respiratory symptoms, urticaria (hives), facial swelling, or other allergic manifestations following administration. Previous adverse reactions to systemic corticosteroids may suggest increased risk of reactions to inhaled forms, though cross-reactivity between different corticosteroid preparations is not universal.

Active respiratory infections represent a significant contraindication to initiating or continuing inhaled corticosteroid therapy. Fungal infections of the respiratory tract are particularly concerning, as corticosteroid-induced local immunosuppression could worsen fungal proliferation. Bacterial respiratory infections should generally be treated with appropriate antimicrobials before starting inhaled corticosteroid therapy or resuming treatment after infection develops. Viral respiratory infections should resolve before inhaled corticosteroid use begins. If a horse on inhaled budesonide develops signs of respiratory infection, the veterinarian should evaluate whether temporary discontinuation of corticosteroid therapy is appropriate while the infection is addressed.

Horses with certain metabolic and endocrine conditions require careful evaluation before inhaled budesonide use, and in some situations the medication may be relatively contraindicated. Horses with pituitary pars intermedia dysfunction (PPID or equine Cushing's disease) have compromised immune function and metabolic disturbances that corticosteroids can exacerbate. Similarly, horses with equine metabolic syndrome (EMS) may be susceptible to worsening insulin dysregulation with corticosteroid exposure. The risk of laminitis in these predisposed populations must be weighed against the need for airway inflammation control. If inhaled corticosteroid therapy is deemed necessary, use of the lowest effective dose and vigilant monitoring are essential.

Additional circumstances may contraindicate inhaled budesonide use or require particular caution. Horses with active laminitis or recent laminitis episodes should not receive corticosteroids unless absolutely necessary under close veterinary supervision, even though inhaled therapy poses lower laminitis risk than systemic treatment. Pregnant mares should be treated with caution, as effects of inhaled corticosteroids on equine pregnancy are not fully characterized. Horses with systemic fungal infections or tuberculosis should not receive corticosteroid therapy. Practical considerations such as inability to effectively administer inhaled medication due to behavioral issues, severe nasal obstruction, or lack of appropriate delivery equipment may also preclude use of inhaled budesonide.

Understanding potential drug interactions is important when using inhaled budesonide as part of a comprehensive respiratory management program. While the localized delivery of inhaled corticosteroids results in reduced systemic exposure compared to oral or injectable administration, some systemic absorption occurs and may contribute to interactions with other medications. Additionally, inhaled budesonide is commonly used alongside other respiratory medications, and understanding how these agents work together supports optimal disease management.

Concurrent use of inhaled budesonide with other corticosteroids results in cumulative corticosteroid exposure that may increase adverse effect risk. Horses receiving systemic corticosteroids such as dexamethasone or prednisolone may be transitioned to inhaled maintenance therapy, but simultaneous use should be carefully managed to avoid excessive total corticosteroid load. The veterinarian will establish appropriate protocols for tapering systemic treatment while initiating or continuing inhaled therapy. Topical corticosteroid preparations applied elsewhere on the body, including those in DMSO combinations, contribute to total corticosteroid exposure and should be considered in the overall management plan.

Inhaled budesonide is frequently combined with bronchodilator medications for comprehensive management of equine asthma. Inhaled beta-agonist bronchodilators like albuterol or anticholinergic bronchodilators like ipratropium provide rapid relief of bronchospasm and may be used for rescue therapy or in routine combination with daily inhaled corticosteroid treatment. When using multiple inhaled medications, the bronchodilator is typically administered first to dilate the airways, potentially enhancing delivery of the subsequently administered corticosteroid to the lower respiratory tract. The veterinarian will specify the appropriate timing and sequence when multiple inhaled medications are prescribed.

NSAID use in horses receiving inhaled budesonide warrants consideration due to the combined risk of gastrointestinal complications when corticosteroids and NSAIDs are used together. While this risk is lower with inhaled corticosteroid therapy than systemic administration, horses on long-term inhaled budesonide who also require NSAID therapy may benefit from gastroprotective measures. The standard recommendation to avoid simultaneous corticosteroid and NSAID use or to provide adequate washout periods applies, though clinical significance is reduced with lower systemic absorption from inhaled therapy. Discuss any concurrent NSAID use with the veterinarian managing the respiratory condition.

Competition horses must consider regulatory implications of budesonide use, as inhaled corticosteroids are prohibited or controlled substances under most competition rules. Detection times for inhaled budesonide have been studied and published in regulatory guidance documents. Owners and trainers of competition horses should maintain accurate medication records and consult current FEI, USEF, or applicable racing commission regulations. The veterinarian can provide guidance on recommended withdrawal times, but ultimate responsibility for compliance rests with the owner and trainer. Individual variation in drug metabolism may affect detection times, so when competition eligibility is uncertain, horses should not compete until adequate clearance time has elapsed.

Appropriate monitoring during inhaled budesonide therapy helps ensure treatment efficacy and allows early detection of adverse effects. Horse owners should observe respiratory function daily, noting coughing, breathing rate and effort, and exercise tolerance. Clinical improvement with inhaled corticosteroids occurs gradually over days to weeks of consistent treatment rather than immediately. The veterinarian will schedule follow-up examinations to objectively assess treatment response, potentially including endoscopic examination of the airways, bronchoalveolar lavage cytology, or lung function testing. These objective measures guide therapy optimization and confirm adequate disease control.

Special populations of horses require additional precautions when using inhaled budesonide. Foals and young horses have different drug metabolism characteristics than adults, and pediatric dosing guidelines for inhaled corticosteroids in horses are not well established. Geriatric horses, especially those with PPID, face increased risk from corticosteroid therapy and require careful monitoring. Pregnant mares should receive inhaled corticosteroids only when benefits clearly outweigh potential risks. Horses with history of laminitis or metabolic conditions predisposing to laminitis need close monitoring of hoof health during treatment, even though inhaled therapy presents lower laminitis risk than systemic corticosteroid use. Individual horse factors should guide treatment decisions and monitoring intensity.

Competition and performance horse considerations are important for inhaled corticosteroid use. Budesonide is a prohibited or controlled substance under FEI regulations, USEF rules, and racing commission guidelines. Pharmacokinetic studies have established detection times, and regulatory bodies publish withdrawal recommendations. However, detection time and withdrawal time differ, and individual metabolic variation may result in prolonged detection in some horses. Horse owners must verify current regulations from the relevant governing body, maintain detailed treatment records including dates, doses, formulations, and batch numbers, and allow sufficient time between last treatment and competition. When eligibility is uncertain, do not compete.

Environmental management is essential alongside inhaled budesonide for effective equine asthma control and cannot be overemphasized. Medication alone cannot overcome ongoing exposure to allergens and respiratory irritants. Effective environmental measures include soaking or steaming hay, using low-dust bedding such as paper, cardboard, or specific dust-free products, improving barn ventilation, removing horses from enclosed spaces during stall cleaning, and maximizing turnout time when possible. Horses with severe disease may need complete turnout management with round bale hay fed at ground level to minimize respirable particle inhalation. The veterinarian can provide specific environmental recommendations based on the individual horse's situation.

Long-term inhaled budesonide use requires periodic veterinary reassessment. While inhaled therapy carries lower risk than systemic treatment, prolonged use may lead to local respiratory tract effects and some degree of systemic absorption. Regular evaluation determines whether continued treatment remains appropriate, whether dose adjustments are indicated, and whether the management approach needs modification. Treatment goals should be periodically reviewed, environmental management measures reinforced, and the horse's overall health status assessed. Do not adjust inhaled corticosteroid dosing without veterinary guidance, as both under-treatment and over-treatment can compromise outcomes.

Proper storage of budesonide inhalation products maintains medication stability and ensures consistent therapeutic delivery. Storage requirements differ somewhat between nebulizer suspensions and metered-dose inhalers, so following product-specific instructions is important. Generally, budesonide products should be stored at controlled room temperature, between 59°F and 77°F (15°C and 25°C), protected from excessive heat, cold, and light exposure. Avoid storing medications in vehicles, unheated tack rooms, or locations with significant temperature fluctuation. Temperature extremes can degrade the medication or affect delivery system performance.

Budesonide nebulizer suspension is typically packaged in single-dose units (respules) or multi-dose vials. Once opened, multi-dose vials should be used within the timeframe specified by the manufacturer, typically within two weeks, even if medication remains. Single-dose units should be used immediately after opening. Store unopened units in their foil overwrap until ready for use to protect from light. Inspect nebulizer suspension before each use; do not use if the liquid appears discolored or contains particles. Discard any unused portion after the recommended period following opening, as sterility and potency cannot be guaranteed.

Metered-dose inhalers require appropriate handling as pressurized containers. Do not puncture, crush, or incinerate inhaler canisters, and do not expose to temperatures above 120°F (49°C). Shake the inhaler well before each use to ensure proper medication mixing. Prime new inhalers or those unused for extended periods by releasing test actuations into the air before administering to the horse. Track remaining doses using the dose counter if present, and do not continue using inhalers beyond their labeled number of actuations, as remaining doses may not deliver adequate medication. Store inhalers with the mouthpiece cap in place when not in use.

Equine delivery devices, including nebulizer masks and metered-dose inhaler spacers, require regular cleaning and maintenance for proper function and hygiene. After each use, wipe the device to remove residue and allow it to dry. Periodically wash with mild soap and water per manufacturer instructions, ensuring complete drying before next use. Inspect devices regularly for damage, wear, or valve malfunction that could affect drug delivery. Replace devices according to manufacturer recommendations or if damage is observed. Properly functioning delivery equipment is essential for effective medication administration.

Dispose of expired or unused budesonide products according to local pharmaceutical waste regulations. Do not use medications beyond their expiration date, as potency and safety cannot be assured. Keep all medications secured away from children and animals to prevent accidental exposure. Maintain medications in their original containers with labeling intact to ensure proper identification and access to expiration dates and lot numbers for treatment records.

Draft horse breeds including Clydesdales, Percherons, Shires, and Belgians present specific considerations for inhaled budesonide therapy related to their larger body size and airway dimensions. The larger lungs of draft breeds may require dose adjustments to achieve therapeutic concentrations in the airways comparable to those attained in lighter breeds with standard protocols. Nebulization may be particularly suitable for draft breeds as it allows delivery of larger total doses over the treatment period. Equipment sizing is also relevant; ensure that nebulizer masks or metered-dose inhaler spacers fit properly to create an effective seal and minimize medication waste. Despite their size, draft horses can develop equine asthma and generally respond well to inhaled corticosteroid therapy when appropriate dosing is achieved.

Light horse breeds such as Thoroughbreds, Arabians, Quarter Horses, and their crosses represent the majority of horses treated with inhaled budesonide for respiratory conditions. Inflammatory airway disease is particularly prevalent in young racing and performance horses of these breeds. Standard dosing protocols are typically appropriate for light horses, though individual variation in treatment response occurs. Some hot-blooded horses may be reactive during medication administration, particularly early in treatment; patience and positive training approaches help improve cooperation. Establishing a consistent routine for treatment administration supports both compliance and horse acceptance.

Ponies and miniature horses require dosing considerations when using inhaled budesonide. Although inhalation therapy dosing is not strictly weight-based, the smaller airway dimensions of ponies and miniatures may result in different relative drug exposure compared to full-sized horses. Equipment fit is important; standard equine delivery devices may not seal properly on small muzzles, potentially compromising drug delivery. Pony-specific masks or modified techniques may be needed. Ponies have higher prevalence of equine metabolic syndrome and associated laminitis risk, making careful monitoring essential during any corticosteroid therapy, even though inhaled administration presents lower systemic risk than oral or injectable routes.

Breed-specific health conditions warrant consideration in treatment planning. Warmbloods have relatively high incidence of equine asthma compared to some other breeds and frequently require long-term respiratory management with inhaled corticosteroids. Horses with Warmblood Fragile Foal Syndrome (WFFS) have compromised tissue integrity, though this primarily affects neonates. Friesians demonstrate documented sensitivity to certain medications and may warrant conservative dosing with close monitoring for adverse effects. No specific contraindications to inhaled budesonide have been established for Arabian horses, Appaloosas, or other breeds, but individual variation exists. Treatment protocols should be individualized based on horse response, with veterinary guidance for any breed-specific concerns.

Within the class of inhaled corticosteroids for equine respiratory disease, several alternatives to budesonide offer different characteristics that may influence medication selection. Beclomethasone dipropionate is a commonly used alternative with established efficacy in equine asthma management. Fluticasone propionate provides high glucocorticoid potency and may offer lower systemic absorption due to its pharmacokinetic profile. Ciclesonide represents a newer option that is activated within the lungs, potentially providing advantages in terms of local activation and minimized systemic effects. Selection among inhaled corticosteroids may depend on individual horse response, veterinarian experience and preference, availability, cost, and delivery method options. Horses that do not respond adequately to one inhaled corticosteroid may benefit from switching to an alternative.

Systemic corticosteroids provide an alternative or adjunctive approach for horses with severe equine asthma or those unable to receive effective inhaled therapy. Dexamethasone and prednisolone are commonly used systemically, providing potent anti-inflammatory effects throughout the body. Systemic therapy is often necessary for initial stabilization of severe cases before transitioning to inhaled maintenance treatment. It may also be appropriate when inhaled administration is not feasible due to horse behavior, equipment limitations, or other factors. However, systemic corticosteroids carry substantially higher risks of adverse effects including laminitis, immunosuppression, and metabolic disturbances compared to inhaled therapy. The goal in most cases is to transition from systemic to inhaled treatment to maintain disease control with reduced risk.

Complementary therapies support comprehensive management of equine respiratory conditions alongside inhaled corticosteroid treatment. Inhaled bronchodilators including albuterol (beta-agonist) and ipratropium (anticholinergic) provide rapid bronchospasm relief and are frequently used in combination with inhaled corticosteroids. Environmental management through dust reduction, ventilation improvement, hay treatment, and modified feeding practices remains fundamental to reducing allergen exposure. Omega-3 fatty acid supplementation may offer modest anti-inflammatory support. For horses with concurrent conditions affecting respiratory health, appropriate management of those issues contributes to overall improvement. Before substituting or adding medications to an established treatment regimen, consult the veterinarian to ensure safe and appropriate integration with the existing management plan.